Vedanta is advancing first-in-class Live Biotherapeutic Products (LBP) to treat serious gastrointestinal diseases using defined consortia of bacteria.
Gut dysbiosis is a known driver of gastrointestinal diseases. Our drugs can stimulate a range of protective responses which hold potential for the treatment of these diseases.
We are developing oral therapies using defined bacterial consortia to treat a range of debilitating diseases with an initial focus on prevention of recurrent Clostridium difficile infection.
Vedanta is conducting clinical trials in recurrent Clostridium difficile infection to evaluate the efficacy and safety of potential drug candidates.